Sunday, December 22

Tag: healthcare

Change Healthcare’s New Ransomware Nightmare Goes From Bad to Worse
16Apr By adminNo Comments
Technology

Change Healthcare’s New Ransomware Nightmare Goes From Bad to Worse

Change Healthcare is facing a new cybersecurity nightmare after a ransomware group began selling what it claimed is Americans’ sensitive medical and financial records stolen from the health care giant.“For most US individuals out there doubting us, we probably have your personal data,” the RansomHub gang said in an announcement seen by WIRED.The stolen data allegedly includes medical and dental records, payment claims, insurance details, and personal information like Social Security numbers and email addresses, according to screenshots. RansomHub claimed it had health care data on active-duty US military personnel.The sprawling theft and sale of sensitive health care data represents a dramatic new form of fallout from the February cyberattack on Change Healthcare that crippled the company...
Read More
Change Healthcare Faces Another Ransomware Threat—and It Looks Credible
13Apr By adminNo Comments
Technology

Change Healthcare Faces Another Ransomware Threat—and It Looks Credible

For months, Change Healthcare has faced an immensely messy ransomware debacle that has left hundreds of pharmacies and medical practices across the United States unable to process claims. Now, thanks to an apparent dispute within the ransomware criminal ecosystem, it may have just become far messier still.In March, the ransomware group AlphV, which had claimed credit for encrypting Change Healthcare’s network and threatened to leak reams of the company’s sensitive health care data, received a $22 million payment—evidence, publicly captured on Bitcoin’s blockchain, that Change Healthcare had very likely caved to its tormentors’ ransom demand, though the company has yet to confirm that it paid. But in a new definition of a worst-case ransomware, a different ransomware group claims to be hol...
Read More
HCLTech announces alliance with Google Cloud to scale Gemini to global cos | Company News
3Apr By adminNo Comments
Business

HCLTech announces alliance with Google Cloud to scale Gemini to global cos | Company News

IT services firm HCL Technologies (HCLTech) on Wednesday said it has expanded alliance with Google Cloud to create industry solutions by using the US tech giant's multimodal large language AI model, Gemini. HCLTech will familiarise and train its 25,000 engineers on Gemini for Google Cloud to help mutual clients innovate and optimise their businesses with GenAI (generative AI), according to a release. With this, HCLTech can offer expertise and technical skill sets that customers require for deploying and managing GenAI projects. HCLTech will enable 25,000 engineers on Google Cloud's latest GenAI technology to support clients at various stage of their AI projects, including the development of new use cases and capabilities for HCLTech platforms and product offeri...
Read More
Startups Are Using AI to Predict Responses to Cancer Drugs
28Dec By adminNo Comments
World

Startups Are Using AI to Predict Responses to Cancer Drugs

Dec. 28, 2023 12:01 pm ET|WSJ ProBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
27Dec By adminNo Comments
Money

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how good your cancer or diabetes drug is, healthcare systems will still have to keep paying for heart disease and rheumatoid arthritis treatments too.That, in a nutshell, is why the divergence of obesity-diabetes companies from the rest of the industry in recent years can’t go on forever. In 2023, Eli Lilly and Novo Nordisk have risen more than 50% each, to become the two largest pharma companies by market capitalization, with their combined value now hovering around $1 trillion. By comparison, the rest of the industry badly underperformed the market, with the NYSE Arca Pharmaceutical Index rising a measly 4% compared with 24% for the S&P 500.  ...
Read More
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
27Dec By adminNo Comments
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:33 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion
27Dec By adminNo Comments
World

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.The upfront cash portion of the deal is $1.0 billion, a 62.0% premium to Gracell’s last closing price for its American depository shares of $6.19, AstraZeneca said in a statement Tuesday.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
How to Ride the Biotech Roller Coaster
26Dec By adminNo Comments
Money

How to Ride the Biotech Roller Coaster

With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs.But investing in this industry is tricky because biotech is a sector of haves and have-nots. While every industry has its winners and losers, the gap in biotech is bigger due to the binary nature of drug development. Many companies spend years testing one medical approach or platform. In the end, either the idea works or it doesn’t, and that could be the difference between tripling your investment or losing it all. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
26Dec By adminNo Comments
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:19 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More